๐๐๐ง๐๐ง๐ญ๐๐๐ก ๐ญ๐จ ๐๐๐ข๐ง๐ญ๐ซ๐จ๐๐ฎ๐๐ ๐๐ฎ๐ฌ๐ฏ๐ข๐ฆ๐จ ๐๐๐ฎ๐ฅ๐๐ซ ๐๐ฆ๐ฉ๐ฅ๐๐ง๐ญ ๐๐จ๐ซ...
๐
๐๐ ๐๐ฅ๐๐๐ซ๐ฌ ๐๐ฎ๐ฆ๐ข๐๐ก๐๐ซ๐โ๐ฌ ๐๐๐ฅ๐๐๐ ๐๐ก๐๐ซ๐๐ฉ๐ฒ ๐๐จ๐ซ ๐๐ซ๐ฒ ๐๐๐
๐ LumiThera, Inc. has received FDA authorization for its Valedaยฎ Light Delivery System, marking a significant advancement in the treatment of dry age-related macular degeneration (AMD), a leading cause of vision loss in older adults. Valeda is the first authorized therapy for this condition and has shown to improve best corrected visual acuity over 24 months in clinical trials. The device utilises Photobiomodulation to potentially preserve retinal anatomy and reduce progression to geographic atrophy. This non-invasive treatment offers hope for early intervention in dry AMD patients.
